Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease

Journal of Renal Nutrition

Volumn 24, Issue 2, 2014, Pages 65-71

  Silbernagel, Guenther ^a,b   Baumgartner, Iris ^a   Wanner, Christoph ^c   März, Winfried ^d,e,f  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; POLYAMINE; SEVELAMER;

BLOOD; CARDIOVASCULAR DISEASE; CHOLESTEROL INTAKE; CHRONIC KIDNEY FAILURE; DIET THERAPY; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; KIDNEY FAILURE, CHRONIC; PHYTOSTEROLS; POLYAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK FACTORS;

EID: 84894287501     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.11.001     Document Type: Review

References (68)

1. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
2. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008, 358:1240-1249.
3. Krane V., Winkler K., Drechsler C., Lilienthal J., März W., Wanner C., German Diabetes and Dialysis Study Investigators Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am J Kidney Dis 2009, 54:902-911.
4. Shoji T., Masakane I., Watanabe Y., Iseki K., Tsubakihara Y., Committee of Renal Data Registry, Japanese Society for Dialysis Therapy Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:1112-1120.
5. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
6. Kovesdy C.P., Anderson J.E., Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007, 18:304-311.
7. Ritz E., Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008, 19:1065-1070.
8. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. Cholesterol Treatment Trialists' (CTT) Collaborators.
9. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
10. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of datafrom 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
11. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248. German Diabetes and Dialysis Study Investigators.
12. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407. AURORA Study Group.
13. Mackay D.S., Jones P.J. Plasma non cholesterol sterols: current uses, potential and need for standardization. Curr Opin Lipidol 2012, 23:241-247.
14. Costet P. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther 2010, 126:263-278.
15. Silbernagel G., Chapman M.J., Genser B., et al. High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis. J Am Coll Cardiol 2013, 62:291-299.
16. Silbernagel G., Fauler G., Renner W., et al. The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J Lipid Res 2009, 50:334-341.
17. Silbernagel G., Fauler G., Hoffmann M.M., et al. The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality. J Lipid Res 2010, 51:2384-2393.
18. Silbernagel G., Lütjohann D., Machann J., et al. Cholesterol synthesis is associated with hepatic lipid content and dependent on fructose/glucose intake in healthy humans. Exp Diabetes Res 2012, 2012:361863.
19. Gylling H., Tuominen J.A., Koivisto V.A., Miettinen T.A. Cholesterol metabolism in type 1 diabetes. Diabetes 2004, 53:2217-2222.
20. Miettinen T.A., Tilvis R.S., Kesäniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990, 131:20-31.
21. Miettinen T.A., Tilvis R.S., Kesäniemi Y.A. Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism 1989, 38:136-140.
22. Matysik S., Klünemann H.H., Schmitz G. Gas chromatography-tandem mass spectrometry method for the simultaneous determination of oxysterols, plant sterols, and cholesterol precursors. Clin Chem 2012, 58:1557-1564.
23. Silbernagel G., Genser B., Nestel P., März W. Plant sterols and atherosclerosis. Curr Opin Lipidol 2013, 24:12-17.
24. Simonen P.P., Gylling H., Miettinen T.A. The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes. Atherosclerosis 2007, 19:222-229.
25. Arntzenius A.C., Kromhout D., Barth J.D., et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med 1985, 312:805-811.
26. Estruch R., Martínez-González M.A., Corella D., et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006, 145:1-11. PREDIMED Study Investigators.
27. Plat J., Mackay D., Baumgartner S., Clifton P.M., Gylling H., Jones P.J. Progress and prospective of plant sterol and plant stanol research: report of the Maastricht meeting. Atherosclerosis 2012, 225:521-533.
28. Demonty I., Ras R.T., van der Knaap H.C., et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 2009, 139:271-284.
29. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443. ENHANCE Investigators.
30. Miettinen T.A., Strandberg T.E., Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000, 20:1340-1346.
31. Gylling H., Miettinen T.A. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis 2002, 160:477-481.
32. Descamps O.S., De Sutter J., Guillaume M., Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. Atherosclerosis 2011, 217:308-321.
33. Miettinen T.A., Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998, 316:1127-1130.
34. Couture P., Lamarche B. Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. Curr Opin Lipidol 2013, 24:227-232.
35. Sudhop T., Lütjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
36. Knopp R.H., Gitter H., Truitt T., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003, 24:729-741. Ezetimibe Study Group.
37. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415.
38. Lin X., Racette S.B., Lefevre M., et al. Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. Circulation 2011, 124:596-601.
39. Salen G., von Bergmann K., Lütjohann D., et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004, 109:966-971. Multicenter Sitosterolemia Study Group.
40. Cannon C.P., Giugliano R.P., Blazing M.A., et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826-832. IMPROVE-IT Investigators.
41. Out C., Groen A.K., Brufau G. Bile acid sequestrants: more than simple resins. Curr Opin Lipidol 2012, 23:43-55.
42. Brensike J.F., Levy R.I., Kelsey S.F., et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984, 69:313-324.
43. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
44. Marangon N., Lindholm B., Stenvinkel P. Nonphosphate-binding effects of sevelamer-are they of clinical relevance?. Semin Dial 2008, 21:385-389.
45. Chertow G.M., Burke S.K., Dillon M.A., Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999, 14:2907-2914.
46. Braun J., Asmus H.G., Holzer H., et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004, 62:104-115.
47. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68:1815-1824.
48. Block G.A., Raggi P., Bellasi A., Kooienga L., Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71:438-441.
49. Suki W.N., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72:1130-1137.
50. Xydakis A.M., Guyton J.R., Chiou P., Stein J.L., Jones P.H., Ballantyne C.M. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004, 94:795-797.
51. Rogacev K.S., Pinsdorf T., Weingärtner O., et al. Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 2012, 7:943-948.
52. Fukushima M., Miura S., Mitsutake R., Fukushima T., Fukushima K., Saku K. Cholesterol metabolism in patients with hemodialysis in the presence or absence of coronary artery disease. Circ J 2012, 76:1980-1986.
53. Shekelle R.B., Shryock A.M., Paul O., et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N Engl J Med 1981, 304:65-70.
54. Estruch R., Ros E., Salas-Salvadó J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013, 368:1279-1290. PREDIMED Study Investigators.
55. Slinin Y., Guo H., Gilbertson D.T., et al. Prehemodialysis care by dietitians and first-year mortality after initiation of hemodialysis. Am J Kidney Dis 2011, 58:583-590.
56. Khoueiry G., Waked A., Goldman M., et al. Dietary intake in hemodialysis patients does not reflect a heart healthy diet. J Ren Nutr 2011, 21:438-447.
57. Dempsey M.E., Farquhar J.W., Smith R.E. The effect of beta sitosterol on the serum lipids of young men with arteriosclerotic heart disease. Circulation 1956, 14:77-82.
58. Weingärtner O., Böhm M., Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J 2009, 30:404-409.
59. Anderson J.L., Adams C.D., Antman E.M., et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:e426-e579. 2011 WRITING GROUP MEMBERS; ACCF/AHA TASK FORCE MEMBERS.
60. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
61. Fransen H.P., de Jong N., Wolfs M., et al. Customary use of plant sterol and plant stanol enriched margarine is associated with changes in serum plant sterol and stanol concentrations in humans. J Nutr 2007, 137:1301-1306.
62. Genser B., Silbernagel G., De Backer G., et al. Plant sterols and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2012, 33:444-451.
63. Teupser D., Baber R., Ceglarek U., et al. Genetic regulation of serum phytosterol levels and risk of coronary artery disease. Circ Cardiovasc Genet 2010, 3:331-339.
64. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 2011, 7:e1002260. IBC 50K CAD Consortium.
65. Deloukas P., Kanoni S., Willenborg C., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013, 45:25-33. CARDIoGRAMplusC4D Consortium.
66. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192. SHARP Investigators.
67. Sato K., Nakano K., Katsuki S., et al. Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe. J Atheroscler Thromb 2012, 19:986-998.
68. Plat J., Theuwissen E., Husche C., et al. Oxidised plant sterols as well as oxycholesterol increase the proportion of severe atherosclerotic lesions in female LDL receptor+/- mice. Br J Nutr 2013, http://www.ncbi.nlm.nih.gov/pubmed/23773414.